CTSH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Cognizant Technology Solutions Corp (CTSH) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company has shown solid financial performance and positive analyst sentiment, the recent sharp price drop (-7.16% in the regular market) and oversold technical indicators suggest waiting for stabilization before entering. Additionally, options data shows bearish sentiment, and there are no strong proprietary trading signals to support immediate action.
The stock is currently oversold with RSI_6 at 10.497, indicating potential for a rebound, but the MACD histogram is negative (-1.566) and expanding downward, signaling bearish momentum. The price is below key support levels (S1: 67.622, S2: 63.199), and moving averages are converging, suggesting indecision in the market.
Strong Q4 2025 financial performance with revenue up 4.94% YoY, net income up 18.68% YoY, and EPS up 21.82% YoY.
Positive analyst sentiment with multiple price target increases and recognition of the company's AI-driven growth strategy.
Recent three-year agreement with DAMAC Group to manage IT infrastructure, enhancing operational efficiency.
Significant regular market price drop (-7.16%) and post-market decline (-0.59%), indicating weak investor confidence.
Gross margin dropped by -3.83% YoY in Q4 2025, which could be a concern for long-term profitability.
Bearish sentiment in options trading and lack of proprietary trading signals.
In Q4 2025, Cognizant reported revenue of $5.33 billion (+4.94% YoY), net income of $648 million (+18.68% YoY), and EPS of $1.34 (+21.82% YoY). However, gross margin declined to 31.11% (-3.83% YoY), indicating some pressure on profitability despite strong top-line and bottom-line growth.
Analysts are generally positive on CTSH, with multiple price target increases (ranging from $82 to $107) and recognition of the company's strong performance in Financial Services and AI-driven growth. However, some analysts maintain neutral ratings, citing concerns about valuation and waiting for better entry points.
